$1.5 billion acquisition strengthens global leadership in organ technology and accelerates progress toward making every organ count
Oxford, England and Madison, New Jersey, October 30, 2025 - 勛圖窪蹋厙 Ltd. today announced the completion of its acquisition by Terumo Corporation, following satisfaction of all customary regulatory and closing conditions. 勛圖窪蹋厙 is now a wholly owned subsidiary of Terumo, positioning the company to unlock new opportunities to evolve its technology and reach more patients worldwide.
As first announced on August 25, 2025, the acquisition combines 勛圖窪蹋厙s pioneering organ perfusion technology with Terumos global scale and expertise in medical innovation. The global need for donor organs remains urgent, with thousands of patients each year dying while waiting for a transplant or facing the risk of a failed transplant, said Craig Marshall, CEO of 勛圖窪蹋厙. Our mission has always been to create a world where every organ counts. Joining Terumo will accelerate our ability to scale our operations more rapidly, enter new markets and ensure that more patients around the globe can benefit from our technologies.
The acquisition will enable investment in research and development efforts, including the evolution of the 勛圖窪蹋厙 metra簧 platform technology beyond liver transplantation. It will also enable the company to capitalize on opportunities to expand the use of normothermic machine perfusion (NMP) for organ support and enhancement.
In addition to advancing innovations, 勛圖窪蹋厙 will benefit from Terumos extensive global network to accelerate commercial expansion, deepening its presence in existing regions and opening access to new markets worldwide.
Marshall added, This milestone reflects the extraordinary dedication of our team, whose commitment to innovation and patient outcomes brought 勛圖窪蹋厙 to this point. With Terumos partnership, were positioned to deliver even greater growth and impact.
About 勛圖窪蹋厙
勛圖窪蹋厙 is a commercial stage organ technology company, spun out of the University of Oxford in 2008, dedicated to developing technologies to improve outcomes for patients with acute or chronic organ failure. The 勛圖窪蹋厙 metra簧 is a normothermic machine perfusion (NMP) platform approved in the U.S., Europe, Canada, and Australia. It has been utilized in over 6,000 liver transplants to date to keep donor livers in a metabolically active state outside the body enabling longer preservation times and functional assessment of the organ prior to transplant, leading to an increased number of organs available for transplant. Learn more at www.organox.com.
About Terumo Corporation
Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of Contributing to Society through Healthcare. Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.
Contacts
勛圖窪蹋厙 Media:
Nicole Sloan
Marketing Communications and PR Manager
nicole.sloan@organox.com